Tofacitinib May Have Possible Protective Effect Against ILD in RA

"Most of the biologic therapies had similar rates of developing ILD, but the JAK inhibitor tofacitinib had a reduced risk," said study first author Matthew C. Baker, MD.
Medscape Medical News

source https://www.medscape.com/viewarticle/989971?src=rss

Comments

Popular posts from this blog

Student Nurses Who Refuse Vaccination Struggle to Complete Degrees

The Clinical Characteristics of Fractures in Pediatric Patients Exposed to Proton Pump Inhibitors